ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Scientific, Inc. (NASDAQ:VIVE), a medical technology company inquisitive about females’s health and the remedy of stress urinary incontinence (SUI), as of late announced that this can picture its third quarter 2022 financial results and provide a company exchange after the shut of the U.S. financial markets on Thursday, November 10, 2022. The Firm will succor a convention name and webcast at 5: 00 PM ET the identical day.
The third quarter 2022 results convention name also will most certainly be accessed on Thursday, November 10th at 5: 00 PM ET by dialing 1-833-255-2833 (home) or 1-412-902-6728 (global) or via live webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=N8zzMVtv. Individuals also can furthermore register for the convention name at https://dpregister.com/sreg/10172049/f4c100901f .
A recording of the webcast shall be posted on the Firm’s investor family net yell material following the name at ir.viveve.com and could presumably well be available on-line for 90 days.
Viveve Scientific, Inc. (Viveve), is a females’s health company inquisitive about the remedy of female SUI. Basically based fully in Englewood, Colorado, the Firm is conducting a pivotal U.S. clinical trial called PURSUIT, the utilization of its recent, dual-power remedy for SUI in females. The internationally patented Viveve® Plan contains Cryogen-cooled Monopolar Radiofrequency technology to uniformly provide an endovaginal remedy that is non-ablative. In the U.S., the Viveve Plan is cleared by the Meals and Drug Administration (FDA) for exhaust in customary surgical procedures for electrocoagulation and hemostasis. Global regulatory approvals and clearances possess been obtained for vaginal laxity and/or development in sexual feature and/or urinary incontinence. Viveve’s present commercial and market pattern efforts style out the U.S. and Asia Pacific areas concentrated on urogynecology, urology, and gynecology core specialties.
Viveve obtained FDA approval of its Investigational Instrument Exemption (IDE) utility to conduct the multicenter, randomized, double-blinded, sham-managed PURSUIT trial for development of SUI in females in July 2020, and FDA approval of its requested IDE protocol amendments in December 2020. The clinical trial become as soon as initiated in January 2021, and completion of field enrollment become as soon as announced on December 14, 2021. Completion of field follow-up visits is anticipated by the halt of 2022, and topline results shall be reported almost at the moment thereafter. If obvious, results from the PURSUIT clinical trial also can enhance a recent SUI indication in the U.S.
For extra data search advice from www.viveve.com.
Protected Harbor Commentary
All statements in this press originate which can even be not essentially based fully on historical truth are “ahead-taking a look statements” for the length of the which draw of Fragment 27A of the Securities Act of 1933 and Fragment 21E of the Securities Replace Act of 1934, alongside with, without limitation, implied and impart statements in terms of Viveve Scientific, Inc.’s plans, timelines, or presumptions of results for the PURSUIT trial. While administration has essentially based fully any ahead-taking a look statements incorporated in this press originate on its present expectations, the facts on which such expectations had been essentially based fully also can exchange. These ahead-taking a look statements depend on a series of assumptions pertaining to future events and are field to a series of risks, uncertainties, and varied components, many of which can even be out of doorways of our succor watch over, which can presumably home off proper results to materially fluctuate from such statements. Such risks, uncertainties and varied components consist of, however have to not slight to, the timing, growth and results of our clinical trials, the fluctuation of global economic stipulations, the affect of the recent coronavirus termed COVID-19 on our clinical pattern and regulatory overview and clearances and on the manufacturing, placements and patient utilization of our Viveve Systems, the efficiency of administration and our workers, our capability to carry out financing, our evaluation of strategic conceivable picks, our capability to carry out approval or clearance in the marketplace of our medical instrument for all indications sought, competition, customary economic stipulations and varied components which can even be detailed in our periodic and present experiences available for overview at www.sec.gov. Furthermore, we feature in a extremely competitive and without note altering atmosphere the build recent and unanticipated risks also can arise. Accordingly, merchants must silent not space any reliance on ahead-taking a look statements as a prediction of proper results. We disclaim any procedure to, and undertake no responsibility to, exchange or revise ahead-taking a look statements to contemplate events or conditions that due to the this truth occur or of which we hereafter change into aware, until required by legislation.
Viveve is a registered trademark of Viveve, Inc.
Investor Relatives contacts:
Amato and Companions, LLC
Investor Relatives Counsel
Berry & Firm Public Relatives
SOURCE: Viveve Scientific, Inc.